nodes	percent_of_prediction	percent_of_DWPC	metapath
Vilazodone—CYP3A4—Estropipate—osteoporosis	0.0902	0.158	CbGbCtD
Vilazodone—CYP3A4—Calcitriol—osteoporosis	0.0902	0.158	CbGbCtD
Vilazodone—CYP2D6—Cholecalciferol—osteoporosis	0.0731	0.128	CbGbCtD
Vilazodone—CYP3A4—Ergocalciferol—osteoporosis	0.0721	0.126	CbGbCtD
Vilazodone—CYP3A4—Raloxifene—osteoporosis	0.0602	0.105	CbGbCtD
Vilazodone—CYP3A4—Ethinyl Estradiol—osteoporosis	0.0581	0.102	CbGbCtD
Vilazodone—CYP3A4—Cholecalciferol—osteoporosis	0.0465	0.0815	CbGbCtD
Vilazodone—CYP3A4—Conjugated Estrogens—osteoporosis	0.0427	0.0748	CbGbCtD
Vilazodone—CYP3A4—Estradiol—osteoporosis	0.0375	0.0657	CbGbCtD
Vilazodone—Flatulence—Alendronate—osteoporosis	0.00176	0.0043	CcSEcCtD
Vilazodone—Mental disorder—Ibandronate—osteoporosis	0.00175	0.00427	CcSEcCtD
Vilazodone—Dysgeusia—Alendronate—osteoporosis	0.00175	0.00427	CcSEcCtD
Vilazodone—Malnutrition—Ibandronate—osteoporosis	0.00174	0.00425	CcSEcCtD
Vilazodone—Flatulence—Raloxifene—osteoporosis	0.00173	0.00423	CcSEcCtD
Vilazodone—Dizziness—Calcium Acetate—osteoporosis	0.00172	0.00421	CcSEcCtD
Vilazodone—Libido decreased—Estradiol—osteoporosis	0.00171	0.00419	CcSEcCtD
Vilazodone—Flatulence—Ibandronate—osteoporosis	0.00171	0.00418	CcSEcCtD
Vilazodone—Dysgeusia—Ibandronate—osteoporosis	0.0017	0.00416	CcSEcCtD
Vilazodone—Increased appetite—Estradiol—osteoporosis	0.00169	0.00414	CcSEcCtD
Vilazodone—Dysgeusia—Calcitriol—osteoporosis	0.00166	0.00407	CcSEcCtD
Vilazodone—Connective tissue disorder—Ethinyl Estradiol—osteoporosis	0.00166	0.00405	CcSEcCtD
Vilazodone—Vomiting—Calcium Acetate—osteoporosis	0.00165	0.00405	CcSEcCtD
Vilazodone—Asthenia—Ergocalciferol—osteoporosis	0.00165	0.00403	CcSEcCtD
Vilazodone—Pollakiuria—Zoledronate—osteoporosis	0.00165	0.00403	CcSEcCtD
Vilazodone—Connective tissue disorder—Risedronate—osteoporosis	0.00161	0.00395	CcSEcCtD
Vilazodone—Palpitations—Estropipate—osteoporosis	0.0016	0.00391	CcSEcCtD
Vilazodone—Disturbance in sexual arousal—Estradiol—osteoporosis	0.00158	0.00386	CcSEcCtD
Vilazodone—Eye disorder—Ethinyl Estradiol—osteoporosis	0.00158	0.00385	CcSEcCtD
Vilazodone—Migraine—Estradiol—osteoporosis	0.00156	0.00383	CcSEcCtD
Vilazodone—Agitation—Calcitriol—osteoporosis	0.00156	0.00382	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Etidronic acid—osteoporosis	0.00156	0.00381	CcSEcCtD
Vilazodone—Nausea—Calcium Acetate—osteoporosis	0.00155	0.00378	CcSEcCtD
Vilazodone—Arthralgia—Estropipate—osteoporosis	0.00154	0.00377	CcSEcCtD
Vilazodone—Eye disorder—Risedronate—osteoporosis	0.00154	0.00376	CcSEcCtD
Vilazodone—Connective tissue disorder—Pamidronate—osteoporosis	0.00154	0.00376	CcSEcCtD
Vilazodone—Palpitations—Ibandronate—osteoporosis	0.00153	0.00375	CcSEcCtD
Vilazodone—Paraesthesia—Etidronic acid—osteoporosis	0.00153	0.00375	CcSEcCtD
Vilazodone—Unspecified disorder of skin and subcutaneous tissue—Estropipate—osteoporosis	0.00153	0.00374	CcSEcCtD
Vilazodone—Cardiac disorder—Risedronate—osteoporosis	0.00153	0.00373	CcSEcCtD
Vilazodone—Irritability—Estradiol—osteoporosis	0.00152	0.00371	CcSEcCtD
Vilazodone—Dyspepsia—Etidronic acid—osteoporosis	0.0015	0.00368	CcSEcCtD
Vilazodone—Arthralgia—Raloxifene—osteoporosis	0.00149	0.00365	CcSEcCtD
Vilazodone—Unspecified disorder of skin and subcutaneous tissue—Raloxifene—osteoporosis	0.00148	0.00363	CcSEcCtD
Vilazodone—Arthralgia—Ibandronate—osteoporosis	0.00148	0.00362	CcSEcCtD
Vilazodone—Mental disorder—Ethinyl Estradiol—osteoporosis	0.00148	0.00361	CcSEcCtD
Vilazodone—Convulsion—Calcitriol—osteoporosis	0.00147	0.0036	CcSEcCtD
Vilazodone—Unspecified disorder of skin and subcutaneous tissue—Ibandronate—osteoporosis	0.00147	0.00359	CcSEcCtD
Vilazodone—Malnutrition—Ethinyl Estradiol—osteoporosis	0.00147	0.00359	CcSEcCtD
Vilazodone—Eye disorder—Pamidronate—osteoporosis	0.00146	0.00357	CcSEcCtD
Vilazodone—Cardiac disorder—Pamidronate—osteoporosis	0.00145	0.00355	CcSEcCtD
Vilazodone—Nervous system disorder—Estropipate—osteoporosis	0.00145	0.00354	CcSEcCtD
Vilazodone—Dry mouth—Ibandronate—osteoporosis	0.00145	0.00354	CcSEcCtD
Vilazodone—Mental disorder—Risedronate—osteoporosis	0.00144	0.00352	CcSEcCtD
Vilazodone—Breast disorder—Estradiol—osteoporosis	0.00144	0.00351	CcSEcCtD
Vilazodone—Skin disorder—Estropipate—osteoporosis	0.00144	0.00351	CcSEcCtD
Vilazodone—Malnutrition—Risedronate—osteoporosis	0.00143	0.0035	CcSEcCtD
Vilazodone—Dry mouth—Calcitriol—osteoporosis	0.00141	0.00346	CcSEcCtD
Vilazodone—Flatulence—Risedronate—osteoporosis	0.00141	0.00345	CcSEcCtD
Vilazodone—Feeling abnormal—Etidronic acid—osteoporosis	0.00141	0.00344	CcSEcCtD
Vilazodone—Nervous system disorder—Raloxifene—osteoporosis	0.0014	0.00343	CcSEcCtD
Vilazodone—Connective tissue disorder—Zoledronate—osteoporosis	0.0014	0.00343	CcSEcCtD
Vilazodone—Skin disorder—Raloxifene—osteoporosis	0.00139	0.0034	CcSEcCtD
Vilazodone—Nervous system disorder—Ibandronate—osteoporosis	0.00139	0.0034	CcSEcCtD
Vilazodone—Hyperhidrosis—Raloxifene—osteoporosis	0.00138	0.00338	CcSEcCtD
Vilazodone—Skin disorder—Ibandronate—osteoporosis	0.00138	0.00337	CcSEcCtD
Vilazodone—Hyperhidrosis—Ibandronate—osteoporosis	0.00137	0.00335	CcSEcCtD
Vilazodone—Nausea—Ergocalciferol—osteoporosis	0.00136	0.00334	CcSEcCtD
Vilazodone—Malnutrition—Pamidronate—osteoporosis	0.00136	0.00333	CcSEcCtD
Vilazodone—Skin disorder—Calcitriol—osteoporosis	0.00135	0.0033	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Estropipate—osteoporosis	0.00135	0.00329	CcSEcCtD
Vilazodone—Insomnia—Estropipate—osteoporosis	0.00134	0.00327	CcSEcCtD
Vilazodone—Eye disorder—Zoledronate—osteoporosis	0.00133	0.00326	CcSEcCtD
Vilazodone—Dysgeusia—Pamidronate—osteoporosis	0.00133	0.00326	CcSEcCtD
Vilazodone—Paraesthesia—Estropipate—osteoporosis	0.00133	0.00325	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Alendronate—osteoporosis	0.00133	0.00324	CcSEcCtD
Vilazodone—Cardiac disorder—Zoledronate—osteoporosis	0.00132	0.00324	CcSEcCtD
Vilazodone—Nervousness—Pamidronate—osteoporosis	0.00132	0.00323	CcSEcCtD
Vilazodone—Somnolence—Estropipate—osteoporosis	0.00131	0.00321	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Raloxifene—osteoporosis	0.0013	0.00319	CcSEcCtD
Vilazodone—Dyspepsia—Estropipate—osteoporosis	0.0013	0.00318	CcSEcCtD
Vilazodone—Insomnia—Raloxifene—osteoporosis	0.00129	0.00317	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Ibandronate—osteoporosis	0.00129	0.00316	CcSEcCtD
Vilazodone—Eye disorder—Conjugated Estrogens—osteoporosis	0.00128	0.00314	CcSEcCtD
Vilazodone—Insomnia—Ibandronate—osteoporosis	0.00128	0.00313	CcSEcCtD
Vilazodone—Dyspepsia—Alendronate—osteoporosis	0.00128	0.00313	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Estropipate—osteoporosis	0.00128	0.00312	CcSEcCtD
Vilazodone—Cardiac disorder—Conjugated Estrogens—osteoporosis	0.00128	0.00312	CcSEcCtD
Vilazodone—Fatigue—Estropipate—osteoporosis	0.00127	0.00312	CcSEcCtD
Vilazodone—Paraesthesia—Ibandronate—osteoporosis	0.00127	0.00311	CcSEcCtD
Vilazodone—Pollakiuria—Estradiol—osteoporosis	0.00127	0.0031	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Calcitriol—osteoporosis	0.00126	0.00309	CcSEcCtD
Vilazodone—Dyspepsia—Raloxifene—osteoporosis	0.00126	0.00308	CcSEcCtD
Vilazodone—Insomnia—Calcitriol—osteoporosis	0.00125	0.00307	CcSEcCtD
Vilazodone—Mental disorder—Zoledronate—osteoporosis	0.00125	0.00306	CcSEcCtD
Vilazodone—Agitation—Pamidronate—osteoporosis	0.00125	0.00306	CcSEcCtD
Vilazodone—Dyspepsia—Ibandronate—osteoporosis	0.00125	0.00305	CcSEcCtD
Vilazodone—Malnutrition—Zoledronate—osteoporosis	0.00124	0.00304	CcSEcCtD
Vilazodone—Unspecified disorder of skin and subcutaneous tissue—Ethinyl Estradiol—osteoporosis	0.00124	0.00303	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Raloxifene—osteoporosis	0.00124	0.00302	CcSEcCtD
Vilazodone—Somnolence—Calcitriol—osteoporosis	0.00123	0.00302	CcSEcCtD
Vilazodone—Decreased appetite—Ibandronate—osteoporosis	0.00123	0.00301	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Ibandronate—osteoporosis	0.00122	0.00299	CcSEcCtD
Vilazodone—Fatigue—Ibandronate—osteoporosis	0.00122	0.00299	CcSEcCtD
Vilazodone—Arthralgia—Risedronate—osteoporosis	0.00122	0.00298	CcSEcCtD
Vilazodone—Dysgeusia—Zoledronate—osteoporosis	0.00122	0.00298	CcSEcCtD
Vilazodone—Unspecified disorder of skin and subcutaneous tissue—Risedronate—osteoporosis	0.00121	0.00296	CcSEcCtD
Vilazodone—Decreased appetite—Calcitriol—osteoporosis	0.00121	0.00295	CcSEcCtD
Vilazodone—Mental disorder—Conjugated Estrogens—osteoporosis	0.0012	0.00294	CcSEcCtD
Vilazodone—Feeling abnormal—Alendronate—osteoporosis	0.0012	0.00293	CcSEcCtD
Vilazodone—Malnutrition—Conjugated Estrogens—osteoporosis	0.0012	0.00293	CcSEcCtD
Vilazodone—Dry mouth—Risedronate—osteoporosis	0.00119	0.00291	CcSEcCtD
Vilazodone—Flatulence—Conjugated Estrogens—osteoporosis	0.00118	0.00288	CcSEcCtD
Vilazodone—Convulsion—Pamidronate—osteoporosis	0.00118	0.00288	CcSEcCtD
Vilazodone—Nervous system disorder—Ethinyl Estradiol—osteoporosis	0.00117	0.00287	CcSEcCtD
Vilazodone—Dysgeusia—Conjugated Estrogens—osteoporosis	0.00117	0.00287	CcSEcCtD
Vilazodone—Vision blurred—Zoledronate—osteoporosis	0.00117	0.00286	CcSEcCtD
Vilazodone—Diarrhoea—Etidronic acid—osteoporosis	0.00117	0.00286	CcSEcCtD
Vilazodone—Feeling abnormal—Ibandronate—osteoporosis	0.00117	0.00286	CcSEcCtD
Vilazodone—Tremor—Zoledronate—osteoporosis	0.00116	0.00285	CcSEcCtD
Vilazodone—Skin disorder—Ethinyl Estradiol—osteoporosis	0.00116	0.00285	CcSEcCtD
Vilazodone—Nervousness—Conjugated Estrogens—osteoporosis	0.00116	0.00284	CcSEcCtD
Vilazodone—Arthralgia—Pamidronate—osteoporosis	0.00116	0.00283	CcSEcCtD
Vilazodone—Nervous system disorder—Risedronate—osteoporosis	0.00115	0.0028	CcSEcCtD
Vilazodone—Agitation—Zoledronate—osteoporosis	0.00114	0.00279	CcSEcCtD
Vilazodone—Skin disorder—Risedronate—osteoporosis	0.00113	0.00277	CcSEcCtD
Vilazodone—Vision blurred—Conjugated Estrogens—osteoporosis	0.00113	0.00276	CcSEcCtD
Vilazodone—Palpitations—Zoledronate—osteoporosis	0.0011	0.00269	CcSEcCtD
Vilazodone—Nervous system disorder—Pamidronate—osteoporosis	0.00109	0.00266	CcSEcCtD
Vilazodone—Vomiting—Etidronic acid—osteoporosis	0.00109	0.00266	CcSEcCtD
Vilazodone—Connective tissue disorder—Estradiol—osteoporosis	0.00108	0.00264	CcSEcCtD
Vilazodone—Convulsion—Zoledronate—osteoporosis	0.00108	0.00263	CcSEcCtD
Vilazodone—Hyperhidrosis—Pamidronate—osteoporosis	0.00107	0.00262	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Risedronate—osteoporosis	0.00106	0.0026	CcSEcCtD
Vilazodone—Asthenia—Estropipate—osteoporosis	0.00106	0.00259	CcSEcCtD
Vilazodone—Arthralgia—Zoledronate—osteoporosis	0.00106	0.00259	CcSEcCtD
Vilazodone—Palpitations—Conjugated Estrogens—osteoporosis	0.00106	0.00259	CcSEcCtD
Vilazodone—Insomnia—Risedronate—osteoporosis	0.00106	0.00258	CcSEcCtD
Vilazodone—Unspecified disorder of skin and subcutaneous tissue—Zoledronate—osteoporosis	0.00105	0.00257	CcSEcCtD
Vilazodone—Paraesthesia—Risedronate—osteoporosis	0.00105	0.00256	CcSEcCtD
Vilazodone—Asthenia—Alendronate—osteoporosis	0.00104	0.00255	CcSEcCtD
Vilazodone—Convulsion—Conjugated Estrogens—osteoporosis	0.00104	0.00254	CcSEcCtD
Vilazodone—Dry mouth—Zoledronate—osteoporosis	0.00103	0.00253	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Ethinyl Estradiol—osteoporosis	0.00103	0.00253	CcSEcCtD
Vilazodone—Fatigue—Ethinyl Estradiol—osteoporosis	0.00103	0.00253	CcSEcCtD
Vilazodone—Dyspepsia—Risedronate—osteoporosis	0.00103	0.00251	CcSEcCtD
Vilazodone—Eye disorder—Estradiol—osteoporosis	0.00103	0.00251	CcSEcCtD
Vilazodone—Cardiac disorder—Estradiol—osteoporosis	0.00102	0.0025	CcSEcCtD
Vilazodone—Arthralgia—Conjugated Estrogens—osteoporosis	0.00102	0.00249	CcSEcCtD
Vilazodone—Asthenia—Ibandronate—osteoporosis	0.00102	0.00249	CcSEcCtD
Vilazodone—Nausea—Etidronic acid—osteoporosis	0.00101	0.00248	CcSEcCtD
Vilazodone—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—osteoporosis	0.00101	0.00247	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Pamidronate—osteoporosis	0.00101	0.00247	CcSEcCtD
Vilazodone—Diarrhoea—Estropipate—osteoporosis	0.00101	0.00247	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Risedronate—osteoporosis	0.00101	0.00247	CcSEcCtD
Vilazodone—Fatigue—Risedronate—osteoporosis	0.00101	0.00246	CcSEcCtD
Vilazodone—Insomnia—Pamidronate—osteoporosis	0.001	0.00246	CcSEcCtD
Vilazodone—Paraesthesia—Pamidronate—osteoporosis	0.000997	0.00244	CcSEcCtD
Vilazodone—Diarrhoea—Alendronate—osteoporosis	0.000996	0.00244	CcSEcCtD
Vilazodone—Asthenia—Calcitriol—osteoporosis	0.000995	0.00243	CcSEcCtD
Vilazodone—Nervous system disorder—Zoledronate—osteoporosis	0.000994	0.00243	CcSEcCtD
Vilazodone—Feeling abnormal—Ethinyl Estradiol—osteoporosis	0.000987	0.00241	CcSEcCtD
Vilazodone—Somnolence—Pamidronate—osteoporosis	0.000987	0.00241	CcSEcCtD
Vilazodone—Skin disorder—Zoledronate—osteoporosis	0.000985	0.00241	CcSEcCtD
Vilazodone—Hyperhidrosis—Zoledronate—osteoporosis	0.00098	0.0024	CcSEcCtD
Vilazodone—Diarrhoea—Raloxifene—osteoporosis	0.000979	0.0024	CcSEcCtD
Vilazodone—Dyspepsia—Pamidronate—osteoporosis	0.000977	0.00239	CcSEcCtD
Vilazodone—Dizziness—Estropipate—osteoporosis	0.000977	0.00239	CcSEcCtD
Vilazodone—Diarrhoea—Ibandronate—osteoporosis	0.000969	0.00237	CcSEcCtD
Vilazodone—Decreased appetite—Pamidronate—osteoporosis	0.000965	0.00236	CcSEcCtD
Vilazodone—Mental disorder—Estradiol—osteoporosis	0.000963	0.00236	CcSEcCtD
Vilazodone—Dizziness—Alendronate—osteoporosis	0.000962	0.00235	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Pamidronate—osteoporosis	0.000958	0.00234	CcSEcCtD
Vilazodone—Nervous system disorder—Conjugated Estrogens—osteoporosis	0.000957	0.00234	CcSEcCtD
Vilazodone—Malnutrition—Estradiol—osteoporosis	0.000957	0.00234	CcSEcCtD
Vilazodone—Fatigue—Pamidronate—osteoporosis	0.000957	0.00234	CcSEcCtD
Vilazodone—Diarrhoea—Calcitriol—osteoporosis	0.000949	0.00232	CcSEcCtD
Vilazodone—Skin disorder—Conjugated Estrogens—osteoporosis	0.000948	0.00232	CcSEcCtD
Vilazodone—Dizziness—Raloxifene—osteoporosis	0.000946	0.00231	CcSEcCtD
Vilazodone—Hyperhidrosis—Conjugated Estrogens—osteoporosis	0.000944	0.00231	CcSEcCtD
Vilazodone—Flatulence—Estradiol—osteoporosis	0.000943	0.00231	CcSEcCtD
Vilazodone—Vomiting—Estropipate—osteoporosis	0.000939	0.0023	CcSEcCtD
Vilazodone—Dysgeusia—Estradiol—osteoporosis	0.000937	0.00229	CcSEcCtD
Vilazodone—Dizziness—Ibandronate—osteoporosis	0.000937	0.00229	CcSEcCtD
Vilazodone—Nervousness—Estradiol—osteoporosis	0.00093	0.00227	CcSEcCtD
Vilazodone—Vomiting—Alendronate—osteoporosis	0.000925	0.00226	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Zoledronate—osteoporosis	0.000924	0.00226	CcSEcCtD
Vilazodone—Insomnia—Zoledronate—osteoporosis	0.000917	0.00224	CcSEcCtD
Vilazodone—Feeling abnormal—Pamidronate—osteoporosis	0.000915	0.00224	CcSEcCtD
Vilazodone—Paraesthesia—Zoledronate—osteoporosis	0.00091	0.00223	CcSEcCtD
Vilazodone—Vomiting—Raloxifene—osteoporosis	0.00091	0.00223	CcSEcCtD
Vilazodone—Somnolence—Zoledronate—osteoporosis	0.000901	0.0022	CcSEcCtD
Vilazodone—Vomiting—Ibandronate—osteoporosis	0.000901	0.0022	CcSEcCtD
Vilazodone—Tremor—Estradiol—osteoporosis	0.000897	0.00219	CcSEcCtD
Vilazodone—Dyspepsia—Zoledronate—osteoporosis	0.000892	0.00218	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Conjugated Estrogens—osteoporosis	0.000889	0.00218	CcSEcCtD
Vilazodone—Insomnia—Conjugated Estrogens—osteoporosis	0.000883	0.00216	CcSEcCtD
Vilazodone—Vomiting—Calcitriol—osteoporosis	0.000882	0.00216	CcSEcCtD
Vilazodone—Decreased appetite—Zoledronate—osteoporosis	0.000881	0.00216	CcSEcCtD
Vilazodone—Agitation—Estradiol—osteoporosis	0.00088	0.00215	CcSEcCtD
Vilazodone—Nausea—Estropipate—osteoporosis	0.000878	0.00215	CcSEcCtD
Vilazodone—Paraesthesia—Conjugated Estrogens—osteoporosis	0.000877	0.00214	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Zoledronate—osteoporosis	0.000875	0.00214	CcSEcCtD
Vilazodone—Fatigue—Zoledronate—osteoporosis	0.000874	0.00214	CcSEcCtD
Vilazodone—Somnolence—Conjugated Estrogens—osteoporosis	0.000868	0.00212	CcSEcCtD
Vilazodone—Nausea—Alendronate—osteoporosis	0.000864	0.00211	CcSEcCtD
Vilazodone—Dyspepsia—Conjugated Estrogens—osteoporosis	0.000859	0.0021	CcSEcCtD
Vilazodone—Asthenia—Ethinyl Estradiol—osteoporosis	0.000859	0.0021	CcSEcCtD
Vilazodone—Nausea—Raloxifene—osteoporosis	0.00085	0.00208	CcSEcCtD
Vilazodone—Decreased appetite—Conjugated Estrogens—osteoporosis	0.000849	0.00208	CcSEcCtD
Vilazodone—Palpitations—Estradiol—osteoporosis	0.000846	0.00207	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Conjugated Estrogens—osteoporosis	0.000843	0.00206	CcSEcCtD
Vilazodone—Fatigue—Conjugated Estrogens—osteoporosis	0.000842	0.00206	CcSEcCtD
Vilazodone—Nausea—Ibandronate—osteoporosis	0.000842	0.00206	CcSEcCtD
Vilazodone—Asthenia—Risedronate—osteoporosis	0.000838	0.00205	CcSEcCtD
Vilazodone—Feeling abnormal—Zoledronate—osteoporosis	0.000835	0.00204	CcSEcCtD
Vilazodone—Nausea—Calcitriol—osteoporosis	0.000824	0.00202	CcSEcCtD
Vilazodone—Diarrhoea—Ethinyl Estradiol—osteoporosis	0.000819	0.002	CcSEcCtD
Vilazodone—Arthralgia—Estradiol—osteoporosis	0.000815	0.00199	CcSEcCtD
Vilazodone—Unspecified disorder of skin and subcutaneous tissue—Estradiol—osteoporosis	0.000809	0.00198	CcSEcCtD
Vilazodone—Diarrhoea—Risedronate—osteoporosis	0.000799	0.00195	CcSEcCtD
Vilazodone—Dry mouth—Estradiol—osteoporosis	0.000797	0.00195	CcSEcCtD
Vilazodone—Asthenia—Pamidronate—osteoporosis	0.000796	0.00195	CcSEcCtD
Vilazodone—Dizziness—Ethinyl Estradiol—osteoporosis	0.000792	0.00194	CcSEcCtD
Vilazodone—Dizziness—Risedronate—osteoporosis	0.000772	0.00189	CcSEcCtD
Vilazodone—Nervous system disorder—Estradiol—osteoporosis	0.000766	0.00187	CcSEcCtD
Vilazodone—Vomiting—Ethinyl Estradiol—osteoporosis	0.000761	0.00186	CcSEcCtD
Vilazodone—Diarrhoea—Pamidronate—osteoporosis	0.000759	0.00186	CcSEcCtD
Vilazodone—Skin disorder—Estradiol—osteoporosis	0.000759	0.00186	CcSEcCtD
Vilazodone—Hyperhidrosis—Estradiol—osteoporosis	0.000755	0.00185	CcSEcCtD
Vilazodone—Vomiting—Risedronate—osteoporosis	0.000742	0.00182	CcSEcCtD
Vilazodone—Dizziness—Pamidronate—osteoporosis	0.000734	0.0018	CcSEcCtD
Vilazodone—Asthenia—Zoledronate—osteoporosis	0.000727	0.00178	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Estradiol—osteoporosis	0.000712	0.00174	CcSEcCtD
Vilazodone—Nausea—Ethinyl Estradiol—osteoporosis	0.000711	0.00174	CcSEcCtD
Vilazodone—Insomnia—Estradiol—osteoporosis	0.000707	0.00173	CcSEcCtD
Vilazodone—Vomiting—Pamidronate—osteoporosis	0.000706	0.00173	CcSEcCtD
Vilazodone—Paraesthesia—Estradiol—osteoporosis	0.000702	0.00172	CcSEcCtD
Vilazodone—Asthenia—Conjugated Estrogens—osteoporosis	0.0007	0.00171	CcSEcCtD
Vilazodone—Somnolence—Estradiol—osteoporosis	0.000695	0.0017	CcSEcCtD
Vilazodone—Diarrhoea—Zoledronate—osteoporosis	0.000694	0.0017	CcSEcCtD
Vilazodone—Nausea—Risedronate—osteoporosis	0.000694	0.0017	CcSEcCtD
Vilazodone—Dyspepsia—Estradiol—osteoporosis	0.000688	0.00168	CcSEcCtD
Vilazodone—Decreased appetite—Estradiol—osteoporosis	0.000679	0.00166	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Estradiol—osteoporosis	0.000675	0.00165	CcSEcCtD
Vilazodone—Fatigue—Estradiol—osteoporosis	0.000674	0.00165	CcSEcCtD
Vilazodone—Dizziness—Zoledronate—osteoporosis	0.00067	0.00164	CcSEcCtD
Vilazodone—Diarrhoea—Conjugated Estrogens—osteoporosis	0.000668	0.00163	CcSEcCtD
Vilazodone—Nausea—Pamidronate—osteoporosis	0.000659	0.00161	CcSEcCtD
Vilazodone—Dizziness—Conjugated Estrogens—osteoporosis	0.000646	0.00158	CcSEcCtD
Vilazodone—Vomiting—Zoledronate—osteoporosis	0.000645	0.00158	CcSEcCtD
Vilazodone—Feeling abnormal—Estradiol—osteoporosis	0.000644	0.00157	CcSEcCtD
Vilazodone—Vomiting—Conjugated Estrogens—osteoporosis	0.000621	0.00152	CcSEcCtD
Vilazodone—Nausea—Zoledronate—osteoporosis	0.000602	0.00147	CcSEcCtD
Vilazodone—Nausea—Conjugated Estrogens—osteoporosis	0.00058	0.00142	CcSEcCtD
Vilazodone—Asthenia—Estradiol—osteoporosis	0.000561	0.00137	CcSEcCtD
Vilazodone—Diarrhoea—Estradiol—osteoporosis	0.000535	0.00131	CcSEcCtD
Vilazodone—Dizziness—Estradiol—osteoporosis	0.000517	0.00126	CcSEcCtD
Vilazodone—Vomiting—Estradiol—osteoporosis	0.000497	0.00122	CcSEcCtD
Vilazodone—Nausea—Estradiol—osteoporosis	0.000464	0.00114	CcSEcCtD
Vilazodone—HTR1A—GPCR ligand binding—PTH1R—osteoporosis	0.000137	0.00668	CbGpPWpGaD
Vilazodone—HTR1A—GPCR ligand binding—CALCR—osteoporosis	0.000137	0.00668	CbGpPWpGaD
Vilazodone—CYP3A4—Farnesoid X Receptor  Pathway—IRS2—osteoporosis	0.000135	0.00659	CbGpPWpGaD
Vilazodone—SLC6A4—NRF2 pathway—AGER—osteoporosis	0.00013	0.00634	CbGpPWpGaD
Vilazodone—DRD2—GPCR ligand binding—CALCR—osteoporosis	0.00012	0.00586	CbGpPWpGaD
Vilazodone—DRD2—GPCR ligand binding—PTH1R—osteoporosis	0.00012	0.00586	CbGpPWpGaD
Vilazodone—CYP3A4—Phase 1 - Functionalization of compounds—CYP27A1—osteoporosis	0.000116	0.00567	CbGpPWpGaD
Vilazodone—HTR1A—G alpha (i) signalling events—CNR2—osteoporosis	0.000116	0.00565	CbGpPWpGaD
Vilazodone—HTR1A—SIDS Susceptibility Pathways—ESR2—osteoporosis	0.000115	0.00562	CbGpPWpGaD
Vilazodone—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP19A1—osteoporosis	0.000115	0.00562	CbGpPWpGaD
Vilazodone—CYP2D6—Oxidation by Cytochrome P450—CYP19A1—osteoporosis	0.000113	0.00554	CbGpPWpGaD
Vilazodone—HTR1A—GPCRs, Class A Rhodopsin-like—CNR2—osteoporosis	0.000107	0.00524	CbGpPWpGaD
Vilazodone—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—osteoporosis	0.000103	0.00506	CbGpPWpGaD
Vilazodone—DRD2—G alpha (i) signalling events—CNR2—osteoporosis	0.000101	0.00496	CbGpPWpGaD
Vilazodone—CYP2D6—Biological oxidations—CYP27A1—osteoporosis	9.42e-05	0.00461	CbGpPWpGaD
Vilazodone—DRD2—GPCRs, Class A Rhodopsin-like—CNR2—osteoporosis	9.42e-05	0.0046	CbGpPWpGaD
Vilazodone—CYP2D6—Phase 1 - Functionalization of compounds—CYP19A1—osteoporosis	9.32e-05	0.00455	CbGpPWpGaD
Vilazodone—CYP3A4—Tryptophan metabolism—CYP19A1—osteoporosis	9.3e-05	0.00454	CbGpPWpGaD
Vilazodone—CYP2D6—Metapathway biotransformation—CYP27A1—osteoporosis	9.29e-05	0.00454	CbGpPWpGaD
Vilazodone—HTR1A—Class A/1 (Rhodopsin-like receptors)—CNR2—osteoporosis	9.19e-05	0.00449	CbGpPWpGaD
Vilazodone—SLC6A4—SIDS Susceptibility Pathways—IL6R—osteoporosis	8.79e-05	0.0043	CbGpPWpGaD
Vilazodone—CYP2C18—Biological oxidations—POMC—osteoporosis	8.71e-05	0.00426	CbGpPWpGaD
Vilazodone—SLC6A4—Circadian rythm related genes—LEP—osteoporosis	8.57e-05	0.00419	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—FDPS—osteoporosis	8.21e-05	0.00401	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—PKM—osteoporosis	8.21e-05	0.00401	CbGpPWpGaD
Vilazodone—DRD2—Class A/1 (Rhodopsin-like receptors)—CNR2—osteoporosis	8.07e-05	0.00394	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—GPD2—osteoporosis	7.78e-05	0.0038	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—PGLS—osteoporosis	7.78e-05	0.0038	CbGpPWpGaD
Vilazodone—HTR1A—GPCR downstream signaling—CALCR—osteoporosis	7.72e-05	0.00377	CbGpPWpGaD
Vilazodone—HTR1A—GPCR downstream signaling—PTH1R—osteoporosis	7.72e-05	0.00377	CbGpPWpGaD
Vilazodone—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—osteoporosis	7.52e-05	0.00367	CbGpPWpGaD
Vilazodone—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—osteoporosis	7.42e-05	0.00363	CbGpPWpGaD
Vilazodone—HTR1A—GPCR ligand binding—PTH—osteoporosis	7.18e-05	0.00351	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—ATIC—osteoporosis	7.12e-05	0.00348	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—PNP—osteoporosis	7.12e-05	0.00348	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—CALCR—osteoporosis	7.01e-05	0.00343	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—PTH1R—osteoporosis	7.01e-05	0.00343	CbGpPWpGaD
Vilazodone—HTR1A—GPCR ligand binding—CNR2—osteoporosis	7e-05	0.00342	CbGpPWpGaD
Vilazodone—CYP2D6—Cytochrome P450 - arranged by substrate type—POMC—osteoporosis	6.91e-05	0.00338	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—PTH1R—osteoporosis	6.78e-05	0.00331	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—CALCR—osteoporosis	6.78e-05	0.00331	CbGpPWpGaD
Vilazodone—SLC6A4—SIDS Susceptibility Pathways—IL1B—osteoporosis	6.69e-05	0.00327	CbGpPWpGaD
Vilazodone—HTR1A—GPCR ligand binding—WNT1—osteoporosis	6.58e-05	0.00321	CbGpPWpGaD
Vilazodone—DRD2—GPCR ligand binding—PTH—osteoporosis	6.3e-05	0.00308	CbGpPWpGaD
Vilazodone—CYP3A4—Biological oxidations—CYP27A1—osteoporosis	6.16e-05	0.00301	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—PTH1R—osteoporosis	6.16e-05	0.00301	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—CALCR—osteoporosis	6.16e-05	0.00301	CbGpPWpGaD
Vilazodone—HTR1A—G alpha (i) signalling events—ADCY5—osteoporosis	6.15e-05	0.00301	CbGpPWpGaD
Vilazodone—DRD2—GPCR ligand binding—CNR2—osteoporosis	6.14e-05	0.003	CbGpPWpGaD
Vilazodone—HTR1A—GPCR downstream signaling—MGLL—osteoporosis	6.14e-05	0.003	CbGpPWpGaD
Vilazodone—HTR1A—SIDS Susceptibility Pathways—IL6R—osteoporosis	6.13e-05	0.00299	CbGpPWpGaD
Vilazodone—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—osteoporosis	6.09e-05	0.00298	CbGpPWpGaD
Vilazodone—CYP3A4—Metapathway biotransformation—CYP27A1—osteoporosis	6.08e-05	0.00297	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—OXCT1—osteoporosis	6.05e-05	0.00296	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—CA2—osteoporosis	6.05e-05	0.00296	CbGpPWpGaD
Vilazodone—HTR1A—GPCR ligand binding—PTHLH—osteoporosis	5.95e-05	0.00291	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—MGLL—osteoporosis	5.9e-05	0.00288	CbGpPWpGaD
Vilazodone—DRD2—GPCR ligand binding—WNT1—osteoporosis	5.78e-05	0.00282	CbGpPWpGaD
Vilazodone—CYP2D6—Phase 1 - Functionalization of compounds—POMC—osteoporosis	5.6e-05	0.00274	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—MGLL—osteoporosis	5.57e-05	0.00272	CbGpPWpGaD
Vilazodone—SLC6A4—NRF2 pathway—TGFB1—osteoporosis	5.48e-05	0.00268	CbGpPWpGaD
Vilazodone—DRD2—G alpha (i) signalling events—ADCY5—osteoporosis	5.4e-05	0.00264	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—MGLL—osteoporosis	5.39e-05	0.00263	CbGpPWpGaD
Vilazodone—DRD2—Circadian rythm related genes—LEP—osteoporosis	5.24e-05	0.00256	CbGpPWpGaD
Vilazodone—HTR1A—GPCR ligand binding—CALCA—osteoporosis	5.24e-05	0.00256	CbGpPWpGaD
Vilazodone—DRD2—GPCR ligand binding—PTHLH—osteoporosis	5.22e-05	0.00255	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—IDH2—osteoporosis	5.02e-05	0.00245	CbGpPWpGaD
Vilazodone—CYP2D6—Biological oxidations—CYP19A1—osteoporosis	4.95e-05	0.00242	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—MGLL—osteoporosis	4.89e-05	0.00239	CbGpPWpGaD
Vilazodone—CYP2D6—Metapathway biotransformation—CYP19A1—osteoporosis	4.88e-05	0.00239	CbGpPWpGaD
Vilazodone—SLC6A4—SIDS Susceptibility Pathways—TNF—osteoporosis	4.85e-05	0.00237	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—CYP27A1—osteoporosis	4.72e-05	0.0023	CbGpPWpGaD
Vilazodone—HTR1A—SIDS Susceptibility Pathways—IL1B—osteoporosis	4.66e-05	0.00228	CbGpPWpGaD
Vilazodone—DRD2—GPCR ligand binding—CALCA—osteoporosis	4.6e-05	0.00225	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—ACP5—osteoporosis	4.59e-05	0.00224	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—SOST—osteoporosis	4.58e-05	0.00224	CbGpPWpGaD
Vilazodone—HTR1A—G alpha (i) signalling events—POMC—osteoporosis	4.53e-05	0.00221	CbGpPWpGaD
Vilazodone—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—osteoporosis	4.52e-05	0.00221	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—TPI1—osteoporosis	4.27e-05	0.00208	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—CALCR—osteoporosis	4.14e-05	0.00202	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—PTH1R—osteoporosis	4.14e-05	0.00202	CbGpPWpGaD
Vilazodone—HTR1A—GPCR downstream signaling—PTH—osteoporosis	4.06e-05	0.00198	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—SOST—osteoporosis	4.02e-05	0.00197	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—P4HB—osteoporosis	4.01e-05	0.00196	CbGpPWpGaD
Vilazodone—DRD2—G alpha (i) signalling events—POMC—osteoporosis	3.97e-05	0.00194	CbGpPWpGaD
Vilazodone—HTR1A—GPCR downstream signaling—CNR2—osteoporosis	3.95e-05	0.00193	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—GAPDH—osteoporosis	3.94e-05	0.00192	CbGpPWpGaD
Vilazodone—SLC6A4—SIDS Susceptibility Pathways—IL6—osteoporosis	3.92e-05	0.00191	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—RAP1A—osteoporosis	3.83e-05	0.00187	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—PTH—osteoporosis	3.68e-05	0.0018	CbGpPWpGaD
Vilazodone—CYP3A4—Phase 1 - Functionalization of compounds—POMC—osteoporosis	3.66e-05	0.00179	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—CALCR—osteoporosis	3.64e-05	0.00178	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—PTH1R—osteoporosis	3.64e-05	0.00178	CbGpPWpGaD
Vilazodone—HTR1A—Class A/1 (Rhodopsin-like receptors)—POMC—osteoporosis	3.6e-05	0.00176	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—CNR2—osteoporosis	3.59e-05	0.00175	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—PTH—osteoporosis	3.56e-05	0.00174	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—CNR2—osteoporosis	3.47e-05	0.0017	CbGpPWpGaD
Vilazodone—HTR1A—SIDS Susceptibility Pathways—TNF—osteoporosis	3.38e-05	0.00165	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—WNT1—osteoporosis	3.38e-05	0.00165	CbGpPWpGaD
Vilazodone—HTR1A—GPCR downstream signaling—PTHLH—osteoporosis	3.36e-05	0.00164	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—MGLL—osteoporosis	3.29e-05	0.00161	CbGpPWpGaD
Vilazodone—CYP3A4—Biological oxidations—CYP19A1—osteoporosis	3.24e-05	0.00158	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—PTH—osteoporosis	3.23e-05	0.00158	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—LRP5—osteoporosis	3.21e-05	0.00157	CbGpPWpGaD
Vilazodone—SLC6A4—Circadian rythm related genes—IL6—osteoporosis	3.2e-05	0.00156	CbGpPWpGaD
Vilazodone—CYP3A4—Metapathway biotransformation—CYP19A1—osteoporosis	3.19e-05	0.00156	CbGpPWpGaD
Vilazodone—DRD2—Class A/1 (Rhodopsin-like receptors)—POMC—osteoporosis	3.16e-05	0.00154	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—CNR2—osteoporosis	3.15e-05	0.00154	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—ENO1—osteoporosis	3.1e-05	0.00151	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—LRP6—osteoporosis	3.07e-05	0.0015	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—PSMA2—osteoporosis	3.05e-05	0.00149	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—PSMA5—osteoporosis	3.05e-05	0.00149	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—PTHLH—osteoporosis	3.05e-05	0.00149	CbGpPWpGaD
Vilazodone—CYP2D6—Biological oxidations—POMC—osteoporosis	2.98e-05	0.00145	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—WNT1—osteoporosis	2.96e-05	0.00145	CbGpPWpGaD
Vilazodone—HTR1A—GPCR downstream signaling—CALCA—osteoporosis	2.96e-05	0.00145	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—PTHLH—osteoporosis	2.95e-05	0.00144	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—MGLL—osteoporosis	2.89e-05	0.00141	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—LRP5—osteoporosis	2.82e-05	0.00138	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—PKM—osteoporosis	2.81e-05	0.00137	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—FDPS—osteoporosis	2.81e-05	0.00137	CbGpPWpGaD
Vilazodone—HTR1A—GPCR ligand binding—POMC—osteoporosis	2.74e-05	0.00134	CbGpPWpGaD
Vilazodone—HTR1A—SIDS Susceptibility Pathways—IL6—osteoporosis	2.73e-05	0.00133	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—LRP6—osteoporosis	2.7e-05	0.00132	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—CALCA—osteoporosis	2.69e-05	0.00131	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—PTHLH—osteoporosis	2.68e-05	0.00131	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—PGLS—osteoporosis	2.66e-05	0.0013	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—GPD2—osteoporosis	2.66e-05	0.0013	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—CALCA—osteoporosis	2.6e-05	0.00127	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—TLN1—osteoporosis	2.59e-05	0.00127	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—CYP19A1—osteoporosis	2.48e-05	0.00121	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—PNP—osteoporosis	2.43e-05	0.00119	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—ATIC—osteoporosis	2.43e-05	0.00119	CbGpPWpGaD
Vilazodone—DRD2—GPCR ligand binding—POMC—osteoporosis	2.41e-05	0.00118	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—CALCA—osteoporosis	2.36e-05	0.00115	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—TLN1—osteoporosis	2.28e-05	0.00111	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—P4HB—osteoporosis	2.24e-05	0.00109	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—PTH—osteoporosis	2.18e-05	0.00106	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—RAP1A—osteoporosis	2.14e-05	0.00105	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—CNR2—osteoporosis	2.12e-05	0.00104	CbGpPWpGaD
Vilazodone—HTR1A—GPCR downstream signaling—ADCY5—osteoporosis	2.11e-05	0.00103	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—NFATC1—osteoporosis	2.09e-05	0.00102	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—DKK1—osteoporosis	2.07e-05	0.00101	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—CA2—osteoporosis	2.07e-05	0.00101	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—OXCT1—osteoporosis	2.07e-05	0.00101	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—ADCY5—osteoporosis	2.02e-05	0.000989	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—GPX1—osteoporosis	2.02e-05	0.000986	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—MGLL—osteoporosis	2.02e-05	0.000985	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—WNT1—osteoporosis	1.99e-05	0.000975	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—P4HB—osteoporosis	1.96e-05	0.00096	CbGpPWpGaD
Vilazodone—DRD2—Circadian rythm related genes—IL6—osteoporosis	1.96e-05	0.000956	CbGpPWpGaD
Vilazodone—CYP3A4—Biological oxidations—POMC—osteoporosis	1.95e-05	0.000951	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—FGA—osteoporosis	1.94e-05	0.000948	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—ADCY5—osteoporosis	1.91e-05	0.000934	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—PTH—osteoporosis	1.91e-05	0.000934	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—RAP1A—osteoporosis	1.88e-05	0.000918	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—CNR2—osteoporosis	1.86e-05	0.00091	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—MTHFR—osteoporosis	1.86e-05	0.00091	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—ADCY5—osteoporosis	1.85e-05	0.000903	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—PKM—osteoporosis	1.83e-05	0.000897	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—FDPS—osteoporosis	1.83e-05	0.000897	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—NFATC1—osteoporosis	1.83e-05	0.000895	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—DKK1—osteoporosis	1.82e-05	0.000888	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—BMP2—osteoporosis	1.8e-05	0.000881	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—PTHLH—osteoporosis	1.8e-05	0.000881	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—FGB—osteoporosis	1.76e-05	0.000862	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—WNT1—osteoporosis	1.75e-05	0.000856	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—PGLS—osteoporosis	1.74e-05	0.00085	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—GPD2—osteoporosis	1.74e-05	0.00085	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—IDH2—osteoporosis	1.71e-05	0.000838	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—PSMA2—osteoporosis	1.7e-05	0.000833	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—PSMA5—osteoporosis	1.7e-05	0.000833	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—FGA—osteoporosis	1.7e-05	0.000832	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—ADCY5—osteoporosis	1.68e-05	0.00082	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—CYP27A1—osteoporosis	1.61e-05	0.000788	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—PNP—osteoporosis	1.59e-05	0.000777	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—ATIC—osteoporosis	1.59e-05	0.000777	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—CALCA—osteoporosis	1.59e-05	0.000776	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—PTHLH—osteoporosis	1.58e-05	0.000774	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—BMP2—osteoporosis	1.58e-05	0.000774	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—ACP5—osteoporosis	1.57e-05	0.000766	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—FGB—osteoporosis	1.55e-05	0.000757	CbGpPWpGaD
Vilazodone—HTR1A—GPCR downstream signaling—POMC—osteoporosis	1.55e-05	0.000757	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—PSMA5—osteoporosis	1.5e-05	0.000731	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—PSMA2—osteoporosis	1.5e-05	0.000731	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—POMC—osteoporosis	1.49e-05	0.000728	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—TPI1—osteoporosis	1.46e-05	0.000712	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—KL—osteoporosis	1.44e-05	0.000705	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—POMC—osteoporosis	1.41e-05	0.000687	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—CALCA—osteoporosis	1.39e-05	0.000681	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—IL6R—osteoporosis	1.37e-05	0.00067	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—P4HB—osteoporosis	1.37e-05	0.00067	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—POMC—osteoporosis	1.36e-05	0.000664	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—CA2—osteoporosis	1.35e-05	0.000661	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—OXCT1—osteoporosis	1.35e-05	0.000661	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—GAPDH—osteoporosis	1.35e-05	0.000657	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—MGLL—osteoporosis	1.32e-05	0.000644	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—RAP1A—osteoporosis	1.31e-05	0.00064	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—KL—osteoporosis	1.27e-05	0.000619	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—POMC—osteoporosis	1.23e-05	0.000603	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—IL6R—osteoporosis	1.2e-05	0.000589	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—ADCY5—osteoporosis	1.13e-05	0.000552	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—IDH2—osteoporosis	1.12e-05	0.000548	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—SPP1—osteoporosis	1.09e-05	0.000534	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—ENO1—osteoporosis	1.06e-05	0.000518	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—CYP27A1—osteoporosis	1.05e-05	0.000515	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—PSMA2—osteoporosis	1.04e-05	0.00051	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—PSMA5—osteoporosis	1.04e-05	0.00051	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—ACP5—osteoporosis	1.03e-05	0.000501	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—ADCY5—osteoporosis	9.92e-06	0.000485	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—IRS2—osteoporosis	9.88e-06	0.000483	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—LEP—osteoporosis	9.67e-06	0.000473	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—SPP1—osteoporosis	9.59e-06	0.000469	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—TPI1—osteoporosis	9.53e-06	0.000466	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—ESR1—osteoporosis	9.23e-06	0.000451	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—P4HB—osteoporosis	8.96e-06	0.000438	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—GAPDH—osteoporosis	8.79e-06	0.00043	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—IRS2—osteoporosis	8.68e-06	0.000424	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—IRS1—osteoporosis	8.63e-06	0.000422	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—RAP1A—osteoporosis	8.57e-06	0.000419	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—LEP—osteoporosis	8.49e-06	0.000415	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—CYP19A1—osteoporosis	8.47e-06	0.000414	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—POMC—osteoporosis	8.31e-06	0.000406	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—ESR1—osteoporosis	8.11e-06	0.000396	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—IL6R—osteoporosis	8.1e-06	0.000396	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—IGF1—osteoporosis	7.99e-06	0.000391	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—IRS1—osteoporosis	7.57e-06	0.00037	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—POMC—osteoporosis	7.29e-06	0.000356	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—IL6R—osteoporosis	7.12e-06	0.000348	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—IGF1—osteoporosis	7.02e-06	0.000343	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—ENO1—osteoporosis	6.92e-06	0.000338	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—ADCY5—osteoporosis	6.92e-06	0.000338	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—GPX1—osteoporosis	6.89e-06	0.000337	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—PSMA2—osteoporosis	6.82e-06	0.000333	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—PSMA5—osteoporosis	6.82e-06	0.000333	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—MTHFR—osteoporosis	6.36e-06	0.000311	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—IL6—osteoporosis	6.11e-06	0.000299	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—CYP19A1—osteoporosis	5.54e-06	0.000271	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—IL6—osteoporosis	5.37e-06	0.000262	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—POMC—osteoporosis	5.09e-06	0.000249	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—MYC—osteoporosis	4.8e-06	0.000235	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—TGFB1—osteoporosis	4.79e-06	0.000234	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—ADCY5—osteoporosis	4.52e-06	0.000221	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—GPX1—osteoporosis	4.51e-06	0.00022	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—MYC—osteoporosis	4.22e-06	0.000206	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—TGFB1—osteoporosis	4.21e-06	0.000206	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—MTHFR—osteoporosis	4.16e-06	0.000203	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—IL6—osteoporosis	3.61e-06	0.000176	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—POMC—osteoporosis	3.33e-06	0.000163	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—IL6—osteoporosis	3.17e-06	0.000155	CbGpPWpGaD
